First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Cancer Discovery

Topics

Biology

Cancer Oncology

Medicine

Internal Medicine

Gastroenterology

Show all topics

DOI

10.1158/2159-8290.cd-17-1119